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Summary
Introduction:	Multiple	sclerosis	 (MS)	 is	an	autoimmune	disease	of	 the	CNS,	which	
predominantly	affects	women.	Studies	 investigating	the	sex	distribution	 in	MS	are	
sparse.	We	aim	to	analyze	the	female‐to‐male	ratio	(F/M	ratio)	in	different	MS	phe‐
notypes	in	association	with	age	at	diagnosis	and	year	of	birth.
Methods:	We	performed	a	retrospective	cross‐sectional	analysis	by	cumulating	data	
(sex,	year	of	birth,	age	at	diagnosis,	and	MS	phenotypes)	from	unpublished	and	pub‐
lished	studies	of	the	participating	centers.
Results:	Datasets	of	945	patients	were	collected.	The	overall	F/M	ratio	was	1.9:1.0	
and	 female	preponderance	was	present	 in	all	phenotypes	except	 for	primary	pro‐
gressive	MS	(PPMS),	in	which	men	were	predominantly	affected	(F/M	ratio:	0.5:1.0).	
Female	preponderance	declined	with	increasing	age	at	diagnosis	and	was	no	longer	
present	in	relapsing‐remitting	MS	(RRMS)	patients	>	58	years	of	age.
Conclusion:	Our	data	demonstrate	an	age	dependency	of	female	preponderance	in	
MS	except	for	PPMS.	This	could	be	influenced	by	the	lifecycle	of	sex	hormone	secre‐
tion	 in	 women.	 In	 PPMS,	 a	 male	 preponderance	 was	 observed	 in	 all	 age‐groups,	
which	might	point	 to	pathophysiological	mechanisms	being	 less	 influenced	by	 sex	
hormones.
K E Y W O R D S
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1  | INTRODUC TION
Similar	to	other	autoimmune	diseases,	multiple	sclerosis	(MS)	has	a	
female	preponderance.1	The	prevalence	of	MS	and	 the	 female‐to‐
male	ratio	 (F/M	ratio)	 in	MS	have	 increased	over	the	 last	decades,	
while age at MS onset has decreased.2	Several	etiological	factors	as‐
sociated	with	modern	lifestyle	are	considered	as	possible	reasons	for	
shifts	in	MS	prevalence,	F/M	ratio,	and	age	at	onset.2,3 Whereas the 
relapsing‐remitting	(RR)	disease	course	has	a	female	preponderance,	
the	 primary	 progressive	 MS	 (PPMS)	 phenotype	 has	 a	 slight	 male	
preponderance	 with	 approximately	 60%	 of	 patients	 being	 male.5 
Summarizing	 data	 from	 different	 studies,	 it	 appears	 that	 age	 at	
onset	influences	sex	distribution	of	RRMS	patients	(F/M	ratio	at	MS	
onset:	<10	years	(y)	1.4:1.0,	18‐49	y	3.1:1.0	and	50‐59	y	2.3:1.0).6,7 
Nevertheless,	 studies	comparing	 the	sex	distribution	between	dif‐
ferent	MS	phenotypes	and	investigating	the	influence	of	age	at	diag‐
nosis	on	the	sex	ratio	are	sparse.
The	aim	of	the	present	study	was	(a)	to	assess	female	prepon‐
derance	in	a	European	cross‐sectional	patient	cohort,	(b)	to	examine	
changes	 in	 the	 F/M	 ratio	 throughout	 the	 last	 decades,	 and	 (c)	 to	
evaluate	sex	ratios	 in	different	MS	phenotypes.	This	may	provide	
a	better	 insight	 into	the	 impact	of	sex	hormones	on	pathophysio‐
logical	mechanisms	 involved	 in	 relapsing	 and	 progressive	 disease	
courses.
2  | METHODS
We	collected	data	of	patients	 treated	at	European	MS	centers	 lo‐
cated	 in	 Athens	 (Greece),	 Bern	 (Switzerland),	 Bochum	 (Germany),	
and	 Peine	 (Germany).	 In	 the	 participating	 centers,	 data	 were	
gathered	 from	medical	 records	and	 from	previously	published	 ret‐
rospective	MS	studies	with	different	nonepidemiological	scopes.8,9 
The	 study	 was	 approved	 by	 the	 responsible	 local	 ethics	 commit‐
tees	 (Eginition	 Hospital,	 Athens	 University	 Medical	 School;	 Bern	
University	Hospital:	KEK‐BE	2017‐01369;	Ruhr‐University	Bochum:	
5408‐15;	Medical	Association	of	Lower	Saxony	(06/17/16)).	The	fol‐
lowing	data	were	assessed:	year	of	birth,	age	at	diagnosis,	sex,	and	
MS	phenotype.	MS	diagnoses	were	included	as	given	in	the	records,	
that	is,	in	accordance	with	the	MS	diagnostic	criteria	used	at	the	re‐
spective	time	of	diagnosis.
F I G U R E  1  Age	at	disease	diagnosis	(mean	±	standard	deviation	
(SD)).	Statistics:	Kruskal‐Wallis	test.	###P < 0.001.
F I G U R E  2   Age at diagnosis 
(mean	±	standard	deviation	(SD))	in	regard	
to	year	of	birth	of	female	and	male	(A)	RIS,	
(B)	CIS,	(C)	RRMS,	and	(D)	PPMS	patients.	
Each	symbol	represents	a	data	point	for	
the	given	episode.	If	a	symbol	is	not	given,	
data	are	missing	for	this	time	interval
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Age	was	used	as	a	continuous	variable	presented	as	mean	and	
standard	 deviation	 (SD),	whereas	 year	 of	 birth	was	 categorized	
for	 our	 analysis.	 Continuous	 variables	 were	 analyzed	 using	 the	
Mann‐Whitney	 test	 (MWT)	 or	 Kruskal‐Wallis	 test	 for	 compari‐
sons	of	more	 than	 two	groups.	A	P‐value	<0.05	was	defined	 as	
significant.
For	the	estimation	of	 the	effect	of	age	at	diagnosis	on	the	sex	
ratio,	we	performed	a	logistic	regression	analysis	with	sex	(dichotom:	
0	=	male,	1	=	female)	as	dependent	and	age	at	diagnosis	as	indepen‐
dent	 variable	 (continuous),	 which	was	 run	 separately	 for	 the	 four	
different	 disease	 courses	 (radiologically	 isolated	 syndrome	 (RIS),	
clinically	isolated	syndrome	(CIS),	RRMS,	and	PPMS).	In	the	regres‐
sion	analysis,	we	defined	significance	as	a	P‐value	<0.013	following	
Bonferroni’s	adjustment	 for	multiple	 testing.	Finally,	 the	predicted	
probabilities	of	female	sex	in	all	four	disease	courses	were	plotted	
against	age	at	diagnosis	to	identify	an	age	cut	off	for	the	switch	of	
sex	preponderance	from	female	to	male.
3  | RESULTS
In	 total,	945	patients	were	retrospectively	analyzed	 (see	Figure	
S1	for	the	distribution	across	centers).	Age	distribution	was	sig‐
nificantly	 different	 between	 MS	 phenotypes.	 Compared	 to	 all	
other	 MS	 phenotypes,	 PPMS	 patients	 were	 older	 at	 diagnosis	
(Figure	1).
Considering	all	MS	phenotypes,	female	patients	(mean	34.0,	SD	
11.4)	were	younger	than	male	patients	at	diagnosis	(mean	38.9,	SD	
12.6;	MWT	P	<	0.001).	In	all	disease	courses	analyzed,	age	at	diag‐
nosis	 decreased	 in	 both	 genders	with	 a	more	 recent	 year	 of	 birth	
(Figure	2).	The	overall	F/M	ratio	irrespective	of	MS	phenotype	was	
1.9:1.0.	It	was	highest	in	RIS	(2.3:1.0)	and	RRMS	(2.0:1.0)	and	lowest	
in	PPMS	patients	(0.5:1.0;	Table	1).	Stratifying	RRMS	patients	by	the	
year	of	birth,	an	increase	in	the	F/M	ratio	with	a	more	recent	year	
of	birth	was	noted	(Figure	3).	Using	logistic	regression	analysis,	we	
demonstrated	that	age	at	RRMS	diagnosis	is	significantly	associated	
with	sex	distribution	with	a	lower	likelihood	of	female	sex	with	older	
age	at	diagnosis	(Table	2).	In	RRMS	patients,	this	creates	a	cut	off	at	
58	years	of	age	at	diagnosis	after	which	the	F/M	ratio	turns	from	a	
female	to	a	male	preponderance	which	is	not	found	in	other	disease	
courses	(Figure	4).
4  | DISCUSSION
The	results	of	this	study	support	previous	findings	on	the	increase	
in	 female	preponderance	over	 the	 last	decades.2,12,13 This might 
reflect	 rather	a	general	epidemiological	phenomenon	than	a	dis‐
ease‐specific	trait.	Moreover,	we	demonstrate	that	female	prepon‐
derance	depends	on	younger	age	at	diagnosis.	Similarly,	a	female	
preponderance	(2.5:1.0)	in	MS	patients	between	20	and	40	years	
of	 age	 but	 a	male	 preponderance	 (1.0:1.5)	 in	 patients	 >50	years	
was	 previously	 reported.14	 A	 decreasing	 age	 at	 diagnosis,	which	
might	contribute	to	an	increase	in	female	preponderance,	was	also	
reported	for	the	Norwegian	county	of	Buskerud.15 The decreasing 
age	at	diagnosis	may	partially	be	explained	by	changes	in	MS	diag‐
nostic	criteria	and	broader	availability	of	diagnostics.	In	line	with	
previous	studies.15,16	an	increasing	female	preponderance	was	also	
reported	by	a	more	recent	epidemiological	study	from	Denmark:	
female	incidence	did	not	only	increase	generally	in	MS,	but	more	
pronounced	in	patients	with	late	disease	onset.18	However,	differ‐
ences	 in	 female	 preponderance	 between	CIS,	 RRMS,	 and	 PPMS	
had	not	been	investigated.	As	demonstrated	in	our	patient	cohort,	
PPMS	patients	were	older	and	had	a	slight	male	preponderance,	
which	 is	also	supported	by	other	cohort	 studies.12,19	The	 female	
preponderance	 in	 RRMS	may	 be	 owed	 to	 sex	 differences	 in	 im‐
mune	 function	 driven	 by	 hormonal	 factors,	which	 predispose	 to	
stronger	autoimmune	responses	in	women.20	On	the	contrary,	the	
neurodegenerative	 component	 and	 the	 progression	 of	 disability	
accumulation	seem	less	pronounced	in	female	compared	to	male	
patients,	which	may	explain	higher	susceptibility	of	male	patients	
for	progressive	disease	courses	like	PPMS.21,22	This	is	further	re‐
inforced	by	experimental	evidence:	 in	experimental	 autoimmune	
encephalomyelitis,	 male	mice	 have	 a	more	 severe	Wallerian	 de‐
generation	in	the	central	nervous	system	than	females.23 Another 
possible	 explanation	 is	 that	 with	 increasing	 age,	 men	 exhibit	 a	
higher	decrease	in	the	expression	of	genes	in	brain	regions	associ‐
ated	with	anabolic	pathways,	including	mitochondrial	energy	pro‐
duction	and	protein	synthesis	than	age‐matched	women.24 These 
pathways	can	be	linked	to	mitochondrial	dysfunction,	which	is	an	
important	factor	in	MS‐associated	neurodegeneration.25
In	the	following,	limitations	of	our	study	will	be	discussed.	As	the	
RRMS	subgroup	represents	approximately	66%	of	all	included	patients	
(n	=	945),	the	other	three	subgroups	and	here	especially	the	numbers	of	
Disease course Female (%) Male (%) Total Female‐to‐male ratio
RIS 36	(69%) 16	(31%) 52 2.3:1.0
CIS 106	(62%) 64	(38%) 170 1.7:1.0
RRMS 417	(67%) 208	(33%) 625 2.0:1.0
PPMS 34	(35%) 64	(65%) 98 0.5:1.0
Total 593	(63%) 352	(37%) 945 1.9:1.0
RRMS
≤58	years 412	(67%) 203	(33%) 615 2.0:1.0
>58	years 5	(50%) 5	(50%) 10 1.0:1.0
TA B L E  1  Gender	distribution	for	
different	MS	phenotypes	and	for	the	age	
cut	off	of	the	RRMS	group
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included	male	patients	were	relatively	small.	Thus,	a	convincing	calcula‐
tion	of	the	F/M	ratio	by	categorized	year	of	birth	was	only	possible	for	
RRMS	patients.	Further,	because	nearly	90%	of	the	patients	were	from	
German	or	Swiss	MS	centers,	a	sampling	bias	with	a	predominant	inclu‐
sion	of	MS	patients	from	these	countries	has	to	be	taken	into	account.	
Another	factor	limiting	data	interpretation	is	the	heterogeneity	of	MS	
diagnostic	 criteria	 used	 over	 time	 in	 patients	 included	 in	 this	 study,	
since these were subject to substantial changes over the last decades.
To	conclude,	our	data	demonstrate	a	varying	female	preponder‐
ance	 in	 different	MS	 disease	 groups.	 Furthermore,	 except	 for	 the	
PPMS	 group,	 an	 age	 dependency	 of	 female	 preponderance	 was	
shown.	Differences	between	MS	phenotypes	may	provide	 further	
insights	 into	pathophysiology	with	 female	sex	hormones	being	as‐
sociated	with	stronger	autoimmune	responses	while	male	sex	hor‐
mones	may	predispose	to	neurodegeneration	during	the	progressive	
phase	of	the	disease.
ACKNOWLEDG MENT
We	thank	Prof.	Ralf	Gold	(Bochum,	Germany)	for	giving	us	the	op‐
portunity	to	work	with	clinical	data	collected	at	the	St.	Josef	Hospital	
in	Bochum,	Germany.
CONFLIC T OF INTERE S T
A	Miclea	 reports	 no	 disclosures.	A	 Salmen	 received	 speaker	 hono‐
raria	and/or	 travel	compensation	 for	activities	with	Almirall	Hermal	
GmbH,	Biogen,	Merck,	Novartis,	Roche	and	Sanofi	Genzyme,	none	
related	to	this	work.	P	Chaloulos‐Iakovidis,	G	Zoehner	report	no	dis‐
closures.	L	Diem	received	travel	grants	from	Merck,	Biogen,	Roche,	
and	 Bayer	 Schweiz.	 CP	 Kamm	 has	 received	 honoraria	 for	 lectures	
as	 well	 as	 research	 support	 from	 Biogen,	 Novartis,	 Almirall,	 Bayer	
Schweiz	 AG,	 Teva,	 Merck,	 Sanofi	 Genzyme,	 Roche,	 Celgene,	 and	
the	Swiss	MS	Society	(SMSG).	M	Miclea	received	travel	grants	from	
Novartis,	Biogen	 Idec,	Bayer,	Teva,	and	Merck	Serono.	K.	Kilidireas	
has	received	travel	grants	and	consulting	fees	from	Biogen,	Novartis,	
Genzyme,	Teva,	and	Merck.	L	Stefanis	reports	no	disclosures	in	rela‐
tion	to	this	work.	M	Briner	received	travel	grants	from	Merck.	A	Chan	
has	received	personal	compensation	for	activities	with	Bayer,	Biogen,	
Genzyme,	Merck,	Novartis,	Roche,	Teva.	He	received	research	sup‐
port	 from	 the	 Swiss	 National	 Fonds	 (SNF,	 No.	 310030_172952),	
Genzyme,	 and	UCB.	ME	Evangelopoulos	has	 received	 travel	 grants	
and	 consulting	 fees	 from	 Biogen,	 Novartis,	 Genzyme,	 Teva,	 and	
Merk.	R	Hoepner	received	research	and	travel	grants	from	Novartis	
and	Biogen	Idec.	He	also	received	speaker’s	honoraria	from	Biogen,	
Novartis,	Merk,	and	Almirall.
DATA ACCE SSIBILIT Y
The	authors	are	willing	 to	 share	 the	data	of	 these	populations	 for	
collaborations.	Please	contact	the	corresponding	author.
ORCID
Anke Salmen  http://orcid.org/0000‐0002‐4751‐299X 
Robert Hoepner  http://orcid.org/0000‐0002‐0115‐7021 
F I G U R E  3  Female‐to‐male	ratio	in	RRMS	patients	stratified	by	
year	of	birth.	Note:	Female‐to‐male	ratios	not	given	for	other	MS	
phenotypes	due	to	low	patient	numbers
TA B L E  2  Logistic	regression	analysis.	Gender	(dichotom	
male	=	0/female	=	1)	is	the	dependent	variable	and	age	at	diagnosis	
(continuous)	the	independent	variable.	Statistic:	Logistic	regression	
analysis
OR 95% CI P‐value R2
RIS 0.99 0.94‐1.04 0.59 0.01
CIS 0.99 0.96‐1.01 0.28 0.01
RRMS 0.97 0.96‐0.99 <0.001 0.02
PPMS 0.98 0.94‐1.02 0.25 0.01
Following	Bonferroni’s	adjustment,	a	significance	can	be	assumed	 if	P‐
value	<0.013.	Significant	P‐values	are	marked	in	bold.
95%	CI,	95%	confidence	interval;	OR,	odds	ratio.
F I G U R E  4  Predicted	probability	of	female	sex	in	regard	to	age	
at	diagnosis.	Predicted	probabilities	were	obtained	by	respective	
logistic	regression	analysis,	which	is	presented	in	detail	in	Table	2
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